Please login to the form below

Not currently logged in


This page shows the latest Zulresso news and features for those working in and with pharma, biotech and healthcare.

Sage slides off a MOUNTAIN as depression drug flunks trial

Sage slides off a MOUNTAIN as depression drug flunks trial

SAGE-217 is an oral follow-up to Sage’s  Zulresso (brexanolone) for postpartum depression (PPD), which was approved by the FDA in March and is delivered by a ... With analysts suggesting that Zulresso’s high cost ($34, 000 at US list price) and

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
How to embrace behavioural science principles in healthcare MR...